The fetal heart monitor tracing in pregnancies complicated by fetal thyrotoxicosis.
Fetal tachycardia caused by the transplacental passage of thyroid stimulating immunoglobulin is well established, but very little information exists regarding the fetal heart rate appearance of this form of tachycardia. Two cases of fetal tachycardia are described in pregnancies complicated by fetal thyrotoxicosis where maternal thyroid history was unknown at the time of testing. For each pregnancy, the fetal heart monitor tracing is depicted and described. In both cases, the initial fetal heart rate pattern demonstrated a sustained baseline of 170 to 180 beats per minute with moderate variability that exhibited accelerations with a lack of decelerations. The tracings were essentially normal except for the baseline rate. When reviewing the differential for fetal tachycardia presenting in the antenatal period, this pattern is unique to fetal thyrotoxicosis, especially if the mother is afebrile and there is no history of medication usage that could explain this presentation.
Towers
Craig V
CV
Long Beach Memorial Women's Hospital, Long Beach, California, USA. drtowers@rbcpress.com
Thomas
Steven
S
Steiger
Ralph M
RM
D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D015148:Cardiotocography; D005260:Female; D005500:Follow-Up Studies; D006340:Heart Rate, Fetal / Q000187:drug effects; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000188:drug therapy; D011256:Pregnancy Outcome; D011441:Propylthiouracil / Q000627:therapeutic use; D013610:Tachycardia / Q000175:diagnosis* / Q000209:etiology*; D013971:Thyrotoxicosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D013974:Thyroxine / Q000627:therapeutic use; D016896:Treatment Outcome
D013956:Antithyroid Agents; D011441:Propylthiouracil; D013974:Thyroxine